Brokerages Set Inozyme Pharma, Inc. (NASDAQ:INZY) PT at $15.71

Inozyme Pharma, Inc. (NASDAQ:INZY) has earned an average rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $15.71.

Several equities research analysts recently issued reports on INZY shares. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Inozyme Pharma in a research note on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and set a $12.00 target price (down from $15.00) on shares of Inozyme Pharma in a research report on Tuesday, November 5th. Stifel Nicolaus assumed coverage on shares of Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price objective (up from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th.

Institutional Trading of Inozyme Pharma

Several hedge funds have recently modified their holdings of the company. Deerfield Management Company L.P. Series C bought a new stake in Inozyme Pharma during the 2nd quarter worth approximately $52,000. Virtu Financial LLC bought a new position in shares of Inozyme Pharma in the third quarter worth about $64,000. Meeder Asset Management Inc. acquired a new position in shares of Inozyme Pharma during the second quarter worth approximately $68,000. Values First Advisors Inc. bought a new stake in shares of Inozyme Pharma during the second quarter valued at approximately $76,000. Finally, SG Americas Securities LLC bought a new position in Inozyme Pharma in the 3rd quarter worth approximately $81,000. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Price Performance

INZY opened at $2.64 on Thursday. The stock has a fifty day moving average price of $4.66 and a 200 day moving average price of $4.83. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a 1 year low of $2.61 and a 1 year high of $7.80. The stock has a market cap of $169.59 million, a price-to-earnings ratio of -1.80 and a beta of 1.54.

Inozyme Pharma (NASDAQ:INZY) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. Analysts forecast that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.